亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Data from Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma

作者
Eudocia Q. Lee,Brian Michael Alexander,Carlos Guillermo Romo,Jeffrey G. Supko,Nathalie Y.R. Agar,Zahra Talebi,Manmeet Singh Ahluwalia,Arati Suvas Desai,Jörg Dietrich,Thomas Joseph Kaley,David M. Peereboom,Jennifer K. Gantchev,Gerard Baquer,Sandro Santagata,Naoko Takebe,Serena Desideri,Joy D. Fisher,Megan Sims,Xiaobu Ye,Keith Lloyd Ligon
标识
DOI:10.1158/1078-0432.c.7722430
摘要

AbstractPurpose: Adavosertib is an oral small-molecule inhibitor of Wee1. The Adult Brain Tumor Consortium conducted a phase I study evaluating adavosertib in combination with radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM), as well as a surgical window-of-opportunity study in recurrent GBM. Patients and Methods: The MTD of adavosertib was determined in adult patients with newly diagnosed GBM using a standard 3+3 design in two separate cohorts: with concurrent RT/TMZ or with adjuvant TMZ. A combination cohort with both concurrent and adjuvant adavosertib at MTD followed. We also performed intratumoral drug distribution studies in patients with recurrent GBM undergoing surgery. Results: As separate cohorts, the MTD for concurrent adavosertib with RT/TMZ was 200 mg daily Monday through Friday × 6 weeks during RT, and the MTD for adjuvant adavosertib with TMZ was 425 mg daily for 5 days of each 28-day cycle. However, six of 12 patients experienced dose-limiting toxicities (DLT) in the combination cohort. The mean ratios of the intratumoral to plasma concentration of adavosertib were 4.18 ± 3.36 for contrast-enhancing tissue and 0.74 ± 0.63 in nonenhancing tissue. Conclusions: Adavosertib at 200 mg daily Monday through Friday × 6 weeks with RT/TMZ and at 425 mg daily on a 5-day/28-day cycle with TMZ had an unacceptable DLT rate. Additional dose levels in combination cohorts resulted in DLT, and we deemed concurrent adavosertib too toxic for further examination. Adavosertib 425 mg daily on a 5-day/28-day cycle with adjuvant TMZ is the recommended phase II dosage. Tissue pharmacokinetics in tissue homogenates and by microdialysis provided complementary information about drug penetration.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
风吹麦浪的应助被听话的老太采纳,获得20
4秒前
于贝贝完成签到,获得积分10
4秒前
4秒前
8秒前
8秒前
n01W97的应助被科研通管家采纳,获得10
8秒前
于贝贝发布了新的文献求助50
9秒前
传奇3的应助被美满冷安采纳,获得10
9秒前
昏睡的映阳完成签到,获得积分10
14秒前
15秒前
17秒前
美满冷安完成签到,获得积分10
20秒前
迪恩发布了新的文献求助10
21秒前
21秒前
美满冷安发布了新的文献求助10
23秒前
29秒前
外向的冰烟完成签到,获得积分10
1分钟前
陈粒完成签到 ,获得积分10
1分钟前
榆庭完成签到,获得积分10
1分钟前
迅速的薯片完成签到,获得积分10
1分钟前
豆豆完成签到,获得积分10
1分钟前
1分钟前
Luella完成签到,获得积分10
1分钟前
1分钟前
mm发布了新的文献求助10
1分钟前
勤恳媚颜完成签到,获得积分10
1分钟前
何何何发布了新的文献求助10
1分钟前
1分钟前
Peiqi的应助被风吹麦浪采纳,获得200
1分钟前
92567发布了新的文献求助10
1分钟前
mm完成签到,获得积分10
1分钟前
aurora333完成签到,获得积分10
1分钟前
Cope完成签到 ,获得积分10
1分钟前
Everything完成签到,获得积分10
2分钟前
2分钟前
哭泣青雪完成签到,获得积分10
2分钟前
金锤锤完成签到,获得积分10
2分钟前
2分钟前
Gp1983发布了新的文献求助30
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190089
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852117
捐赠科研通 7788276
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2559990
邀请新用户注册赠送积分活动 2482862